DealBoehringer Ingelheim enters €410m licenc...Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. more ➔
FinancingmiRNA specialist Resalis Therapeutics Srl...Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity. more ➔
AMRRoche presents restistance-breaking antibi...Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii. . more ➔
CollaborationAlfasigma SpA signs €170m deal with Gala...Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal. more ➔
M&AAstraZeneca buys Chinese Gracell Biotechno... Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn. more ➔
financingMetrion Biosciences closes £3.7m equity...Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures. more ➔
CollaborationLimmaTech Biologics acquires licence optio...Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVaccs preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success. more ➔
Novel FoodFrench parliamentarians against cell-based...The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France. more ➔
FinancingVandria SA bags CHF18m in Series A financi...Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318. more ➔
financingAntabio SAS raises €25 m in Series B fin... Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors. more ➔
